Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Eplontersen

Knowing that you are interested in Eplontersen, we have listed articles on similar topics on the website for your convenience. As a professional manufacturer, we hope that this news can help you. If you are interested in learning more about the product, please feel free to contact us.
  • Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    2025-03-31

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's WAINUA (AUTOINJECTOR), containing active ingredient EPLONTERSEN SODIUM - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - BIOXCEL THERAPEUTICS INC's IGALMI, containing active ingredient DEXMEDETOMIDINE HYDROCHLORIDE - PHARMAAND GMBH's RUBRACA, containing active ingredient RUCAPARIB CAMSYLATE Read More